Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2026 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

conmed corp. - CNMD

CNMD

Close Chg Chg %
40.70 0.84 2.05%

Closed Market

41.54

+0.84 (2.05%)

Volume: 497.51K

Last Updated:

Feb 6, 2026, 3:59 PM EDT

Trade Now

Company Overview: conmed corp. - CNMD

CNMD Key Data

Open

$40.60

 Day Range

40.17 - 41.65

52 Week Range

35.37 - 68.42

 Market Cap

$1.24B

Shares Outstanding

30.97M

 Public Float

30.03M

Beta

0.97

 Rev. Per Employee

N/A

P/E Ratio

26.93

 EPS

$1.52

Yield

196.75%

 Dividend

$0.20

EX-DIVIDEND DATE

Sep 15, 2025

 SHORT INTEREST

N/A

AVERAGE VOLUME

674.89K

  

CNMD Performance

1 Week
 
 8.15%
 
1 Month
 
 -3.24%
 
3 Months
 
 -5.57%
 
1 Year
 
 -37.50%
 
5 Years
 
 -66.20%
 

CNMD Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 6
Full Ratings ➔

About conmed corp. - CNMD

CONMED Corp. is a medical technology company, which engages in providing devices and equipment for surgical procedures. Its products include AirSeal and insufflation, allograft cartilage and tissue, arthroplasty, biliary and endoscopic ultrasound, biomedical sensors and electrodes, biopsy and polypectomy, dilators and accessories, electrosurgical units, fixation devices, hemostasis, implants and suture anchors, infection prevention, patient positioning, and related products. The company was founded by Eugene R. Corasanti in 1970 and is headquartered in Largo, FL.

CNMD At a Glance

CONMED Corp.
11311 Concept Boulevard
Largo, Florida 33773
Phone 1-727-392-6464 Revenue 1.37B
Industry Medical Specialties Net Income 47.06M
Sector Health Technology 2025 Sales Growth 5.526%
Fiscal Year-end 12 / 2026 Employees N/A
View SEC Filings

CNMD Valuation

P/E Current 26.927
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) 26.887
Price to Sales Ratio 0.92
Price to Book Ratio N/A
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA N/A
Enterprise Value to Sales N/A
Total Debt to Enterprise Value N/A

CNMD Efficiency

Revenue/Employee N/A
Income Per Employee N/A
Receivables Turnover N/A
Total Asset Turnover N/A

CNMD Liquidity

Current Ratio N/A
Quick Ratio N/A
Cash Ratio N/A

CNMD Profitability

Gross Margin 53.873
Operating Margin 9.466
Pretax Margin 5.173
Net Margin 3.423
Return on Assets N/A
Return on Equity N/A
Return on Total Capital N/A
Return on Invested Capital N/A

CNMD Capital Structure

Total Debt to Total Equity N/A
Total Debt to Total Capital N/A
Total Debt to Total Assets N/A
Long-Term Debt to Equity N/A
Long-Term Debt to Total Capital N/A
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Conmed Corp. - CNMD

Collapse All in section
All values USD millions. 2022 2023 2024 2025 5-year trend
Sales/Revenue
1.03B 1.24B 1.30B 1.37B
Sales Growth
+1.41% +20.44% +4.98% +5.53%
Cost of Goods Sold (COGS) incl D&A
502.37M 597.89M 608.16M 634.12M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
49.76M 51.40M 51.30M 74.28M
Depreciation
16.05M 16.20M 16.61M 17.14M
Amortization of Intangibles
33.70M 35.20M 34.70M 57.14M
COGS Growth
+5.25% +19.01% +1.72% +4.27%
Gross Income
528.02M 643.07M 694.57M 740.61M
Gross Income Growth
-1.99% +21.79% +8.01% +6.63%
Gross Profit Margin
+51.24% +51.82% +53.32% +53.87%
2022 2023 2024 2025 5-year trend
SG&A Expense
444.39M 512.28M 530.35M 610.48M
Research & Development
47.15M 52.60M 54.43M 55.88M
Other SG&A
397.24M 459.68M 475.92M 554.60M
SGA Growth
+5.23% +15.28% +3.53% +15.11%
Other Operating Expense
- - - -
-
Unusual Expense
141.61M 18.81M (30.69M) 27.86M
EBIT after Unusual Expense
(57.98M) 111.97M 194.92M 102.27M
Non Operating Income/Expense
16.02M 8.63M 5.41M 290.00K
Non-Operating Interest Income
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
28.91M 39.77M 37.30M 31.09M
Interest Expense Growth
-18.54% +37.61% -6.23% -16.65%
Gross Interest Expense
28.91M 39.77M 37.30M 31.09M
Interest Capitalized
- - - -
-
Pretax Income
(70.86M) 80.83M 163.03M 71.12M
Pretax Income Growth
-196.93% +214.06% +101.70% -56.38%
Pretax Margin
-6.88% +6.51% +12.51% +5.17%
Income Tax
9.72M 16.37M 30.61M 24.06M
Income Tax - Current - Domestic
- 1.68M 5.89M 6.96M
Income Tax - Current - Foreign
- 14.08M 9.78M 11.45M
Income Tax - Deferred - Domestic
- (5.73M) 1.93M 11.03M
Income Tax - Deferred - Foreign
- (310.00K) (1.23M) 1.17M
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(80.58M) 64.46M 132.42M 47.05M
Minority Interest Expense
- - - -
-
Net Income
(80.58M) 64.46M 132.42M 47.05M
Net Income Growth
-228.84% +179.99% +105.44% -64.47%
Net Margin Growth
-7.82% +5.19% +10.17% +3.42%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(80.58M) 64.46M 132.42M 47.05M
Preferred Dividends
- - - -
-
Net Income Available to Common
(80.58M) 64.46M 132.42M 47.05M
EPS (Basic)
-2.6825 2.1018 4.293 1.5161
EPS (Basic) Growth
-225.08% +178.35% +104.25% -64.68%
Basic Shares Outstanding
30.04M 30.67M 30.85M 31.04M
EPS (Diluted)
-2.6825 2.0432 4.2511 1.51
EPS (Diluted) Growth
-238.18% +176.17% +108.06% -64.48%
Diluted Shares Outstanding
30.04M 31.55M 31.15M 31.15M
EBITDA
133.38M 182.19M 215.53M 204.41M
EBITDA Growth
-19.76% +36.59% +18.30% -5.16%
EBITDA Margin
+12.94% +14.68% +16.54% +14.87%

Snapshot

Average Recommendation HOLD Average Target Price 48.60
Number of Ratings 6 Current Quarters Estimate 0.818
FY Report Date 03 / 2026 Current Year's Estimate 4.355
Last Quarter’s Earnings 1.43 Median PE on CY Estimate N/A
Year Ago Earnings 4.59 Next Fiscal Year Estimate 4.927
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 6 6 6 6
Mean Estimate 0.82 1.09 4.36 4.93
High Estimates 0.83 1.12 4.38 5.09
Low Estimate 0.81 1.06 4.32 4.81
Coefficient of Variance 0.92 1.83 0.52 2.28

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 1 1 1
OVERWEIGHT 0 0 0
HOLD 5 5 5
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Hold Hold Hold

Insider Actions for Conmed Corp. - CNMD

Date Name Shares Transaction Value
Nov 25, 2025 Richard Glaze Chief Information Officer N/A Open market or private sale of non-derivative or derivative security Non-derivative transaction at $41.21 per share 0.00
Sep 10, 2025 Kim Kelderman Director 500 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Sep 10, 2025 Kim Kelderman Director 6,227 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Apr 9, 2025 Todd W. Garner Executive Vice President & CFO 598 Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $57.37 per share 34,307.26
Apr 7, 2025 Brent Lalomia Executive VP RA, QA 94 Other acquisition or disposition Non-derivative transaction at $68.44 per share 6,433.36
Mar 12, 2025 Brent Lalomia Vice President QA and RA 1,006 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $62.74 per share 63,116.44
Mar 12, 2025 Brent Lalomia Vice President QA and RA 75 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 6, 2025 Pete K. Shagory EVP, STRAT & CORP DEVT 26,127 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 6, 2025 Johonna Pelletier Treasurer and VP, Tax 9,300 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 6, 2025 John Ferrell Executive Vice President - HR 21,516 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 6, 2025 Edward A. Clifford VP Global Manufacturing 26,127 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 6, 2025 Hollie K. Foust General Counsel & Corp Sec 30,738 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 26, 2025 Mark B. Kaye Director 1,846 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 26, 2025 Mark B. Kaye Director 152 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00

Conmed Corp. in the News